RedHill Biopharma Ltd. announced a new Chinese patent for opaganib effective through 2035, focusing on Ebola virus treatment, which previously showed promising survival results in U.S. Army studies. This patent adds to their global intellectual property portfolio and supports multiple potential uses, including other viral infections and cancer therapies.